| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 83,03 | 83,71 | 08:13 | |
| 83,01 | 83,69 | 08:12 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07:42 | Sanofi's Riliprubart Receives Orphan Drug Status In Japan For Rare Nerve Disorder | PARIS (dpa-AFX) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal... ► Artikel lesen | |
| 07:34 | Sanofi: Availability of the Q2 2025 Aide mémoire |
Availability of the Q2 2025 Aide mémoire
Paris, France - June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website:
Second... ► Artikel lesen | |
| 07:10 | Sanofi: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy | Riliprubart granted orphan drug designation in Japan for
chronic inflammatory demyelinating polyneuropathy
Two phase 3 studies are currently underway testing riliprubart in people with CIDP... ► Artikel lesen | |
| Fr | Kymera's partnerships with Sanofi and Gilead drive value | ||
| Fr | Sanofi's Sarclisa recommended by CHMP for new multiple myeloma indication |
